CliffBio
small molecule

ETODOLAC

ETODOLAC

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameETODOLAC
Active ingredientETODOLAC
Strength500MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2002
Marketing statusRX

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.